LLY Relative Valuation
LLY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LLY is overvalued; if below, it's undervalued.
Historical Valuation
Eli Lilly and Co (LLY) is now in the Fair zone, suggesting that its current forward PE ratio of 34.51 is considered Fairly compared with the five-year average of 40.39. The fair price of Eli Lilly and Co (LLY) is between 916.62 to 1488.68 according to relative valuation methord.
Relative Value
Fair Zone
916.62-1488.68
Current Price：1064.04
Fair
34.51
PE
1Y
3Y
5Y
24.94
EV/EBITDA
Eli Lilly and Co. (LLY) has a current EV/EBITDA of 24.94. The 5-year average EV/EBITDA is 30.16. The thresholds are as follows: Strongly Undervalued below 15.09, Undervalued between 15.09 and 22.62, Fairly Valued between 37.70 and 22.62, Overvalued between 37.70 and 45.23, and Strongly Overvalued above 45.23. The current Forward EV/EBITDA of 24.94 falls within the Historic Trend Line -Fairly Valued range.
28.94
EV/EBIT
Eli Lilly and Co. (LLY) has a current EV/EBIT of 28.94. The 5-year average EV/EBIT is 35.13. The thresholds are as follows: Strongly Undervalued below 16.09, Undervalued between 16.09 and 25.61, Fairly Valued between 44.66 and 25.61, Overvalued between 44.66 and 54.18, and Strongly Overvalued above 54.18. The current Forward EV/EBIT of 28.94 falls within the Historic Trend Line -Fairly Valued range.
13.21
PS
Eli Lilly and Co. (LLY) has a current PS of 13.21. The 5-year average PS is 11.11. The thresholds are as follows: Strongly Undervalued below 5.50, Undervalued between 5.50 and 8.30, Fairly Valued between 13.92 and 8.30, Overvalued between 13.92 and 16.72, and Strongly Overvalued above 16.72. The current Forward PS of 13.21 falls within the Historic Trend Line -Fairly Valued range.
40.06
P/OCF
Eli Lilly and Co. (LLY) has a current P/OCF of 40.06. The 5-year average P/OCF is 38.78. The thresholds are as follows: Strongly Undervalued below 16.04, Undervalued between 16.04 and 27.41, Fairly Valued between 50.14 and 27.41, Overvalued between 50.14 and 61.51, and Strongly Overvalued above 61.51. The current Forward P/OCF of 40.06 falls within the Historic Trend Line -Fairly Valued range.
60.79
P/FCF
Eli Lilly and Co. (LLY) has a current P/FCF of 60.79. The 5-year average P/FCF is 51.29. The thresholds are as follows: Strongly Undervalued below 16.90, Undervalued between 16.90 and 34.09, Fairly Valued between 68.48 and 34.09, Overvalued between 68.48 and 85.68, and Strongly Overvalued above 85.68. The current Forward P/FCF of 60.79 falls within the Historic Trend Line -Fairly Valued range.
Eli Lilly and Co (LLY) has a current Price-to-Book (P/B) ratio of 40.68. Compared to its 3-year average P/B ratio of 46.09 , the current P/B ratio is approximately -11.74% higher. Relative to its 5-year average P/B ratio of 39.70, the current P/B ratio is about 2.46% higher. Eli Lilly and Co (LLY) has a Forward Free Cash Flow (FCF) yield of approximately 0.96%. Compared to its 3-year average FCF yield of 0.61%, the current FCF yield is approximately 57.99% lower. Relative to its 5-year average FCF yield of 1.39% , the current FCF yield is about -30.81% lower.
40.68
P/B
Median3y
46.09
Median5y
39.70
0.96
FCF Yield
Median3y
0.61
Median5y
1.39
Competitors Valuation Multiple
The average P/S ratio for LLY's competitors is 7.02, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY) exhibits a P/S ratio of 13.21, which is 88.17% above the industry average. Given its robust revenue growth of 53.87%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LLY increased by 31.19% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 8.48 to 31.72.
The secondary factor is the Revenue Growth, contributed 53.87%to the performance.
Overall, the performance of LLY in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
COST
Costco Wholesale Corp
882.58USD
-0.73%
PFE
Pfizer Inc
25.28USD
-0.59%
JNJ
Johnson & Johnson
207.49USD
1.32%
CRM
Salesforce Inc
266.12USD
1.22%
MRK
Merck & Co Inc
108.6USD
-0.25%
HD
Home Depot Inc
349.06USD
-0.07%
UNH
UnitedHealth Group Inc
341.7USD
-2.08%
BRK.B
Berkshire Hathaway Inc
496.12USD
-0.59%
PG
Procter & Gamble Co
138.04USD
-1.34%
CVX
Chevron Corp
155.2USD
-0.86%
Frequently Asked Questions
Is Eli Lilly and Co (LLY) currently overvalued or undervalued?
Eli Lilly and Co (LLY) is now in the Fair zone, suggesting that its current forward PE ratio of 34.51 is considered Fairly compared with the five-year average of 40.39. The fair price of Eli Lilly and Co (LLY) is between 916.62 to 1488.68 according to relative valuation methord.
What is Eli Lilly and Co (LLY) fair value?
LLY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Eli Lilly and Co (LLY) is between 916.62 to 1488.68 according to relative valuation methord.
How does LLY's valuation metrics compare to the industry average?
The average P/S ratio for LLY's competitors is 7.02, providing a benchmark for relative valuation. Eli Lilly and Co Corp (LLY) exhibits a P/S ratio of 13.21, which is 88.17% above the industry average. Given its robust revenue growth of 53.87%, this premium appears sustainable.
What is the current P/B ratio for Eli Lilly and Co (LLY) as of Jan 07 2026?
As of Jan 07 2026, Eli Lilly and Co (LLY) has a P/B ratio of 40.68. This indicates that the market values LLY at 40.68 times its book value.
What is the current FCF Yield for Eli Lilly and Co (LLY) as of Jan 07 2026?
As of Jan 07 2026, Eli Lilly and Co (LLY) has a FCF Yield of 0.96%. This means that for every dollar of Eli Lilly and Co’s market capitalization, the company generates 0.96 cents in free cash flow.
What is the current Forward P/E ratio for Eli Lilly and Co (LLY) as of Jan 07 2026?
As of Jan 07 2026, Eli Lilly and Co (LLY) has a Forward P/E ratio of 34.51. This means the market is willing to pay $34.51 for every dollar of Eli Lilly and Co’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Eli Lilly and Co (LLY) as of Jan 07 2026?
As of Jan 07 2026, Eli Lilly and Co (LLY) has a Forward P/S ratio of 13.21. This means the market is valuing LLY at $13.21 for every dollar of expected revenue over the next 12 months.